These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15030302)

  • 1. Dyslipidemia treatment: current considerations and unmet needs.
    Malik S; Kashyap ML
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):121-34. PubMed ID: 15030302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy for the treatment of dyslipidemia.
    Streja D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):306-12. PubMed ID: 15083597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
    Jones PH
    Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Balbisi EA
    Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy.
    Vega GL
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):525-44, vi. PubMed ID: 15262295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis].
    Farnier M; Bonnet F; Bruckert E; Ferrières J; Paillard F;
    Arch Mal Coeur Vaiss; 2007; 100(6-7):569-81. PubMed ID: 17893640
    [No Abstract]   [Full Text] [Related]  

  • 14. Colesevelam hydrochloride in the management of dyslipidemia.
    Armani A; Toth PP
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):283-91. PubMed ID: 16716090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations.
    Lavie CJ
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):29-33. PubMed ID: 15133427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.